Australia's most trusted
source of pharma news
Wednesday, 19 November 2025
Posted 18 November 2025 AM
The release of a new report on precision medicine has prompted Johnson & Johnson Managing Director Joana De Castro to warn that without urgent change Australia risks becoming an unviable market.
She said without reform pharma companies will increasingly decide not to pursue registrations or reimbursements for precision medicines in Australia.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.